Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To obtain a comprehensive review of harms following MIGS reported in randomised and non‐randomised studies, clinical study reports submitted to regulatory organisations for approval or postmarketing surveillance and registries. We will also examine the design characteristics, risk of bias, and reporting adequacy of pivotal MIGS trials submitted to the US and EU regulatory organisations regarding harms reporting and analyses.
To obtain a comprehensive review of harms following MIGS reported in randomised and non‐randomised studies, clinical study reports submitted to regulatory organisations for approval or postmarketing surveillance and registries. We will also examine the design characteristics, risk of bias, and reporting adequacy of pivotal MIGS trials submitted to the US and EU regulatory organisations regarding harms reporting and analyses.
Original language | English |
---|---|
Article number | CD015294 |
Journal | Cochrane Database of Systematic Reviews |
Volume | 2022 |
Issue number | 12 |
DOIs | |
Publication status | Published - 14 Dec 2022 |
Keywords
- Pharmacology (medical)